Extended Data from Gilead’s PBC Program Strengthens Case Ahead of FDA Ruling

1. Gilead Sciences has released new long-term data for its Primary Biliary Cholangitis (PBC) program, which is under review by the U.S. Food and Drug Administration (FDA).
2. The extended data provides additional support for Gilead's PBC treatment, offering a more comprehensive understanding of its efficacy and safety over an extended period.
3. Primary Biliary Cholangitis is a chronic liver disease that can lead to cirrhosis, liver failure, and other complications if not treated effectively.
4. The FDA's decision on Gilead's PBC program could significantly impact the treatment options available for patients with this condition.
5. The new data could potentially influence the FDA's decision, as it provides a more robust picture of the treatment's long-term effects.